Filing Flows › Accendra Health (ACH) › Q2 2026 › vs Q1 2026
Accendra Health (ACH) Q2 2026 vs Q1 2026 (quarter over quarter)
Accendra Health's revenue fell $14.5M (-2%) from $628M in Q1 2026 to $613M in Q2 2026. The biggest changes: Sleep therapy −$18.3M (-11%); Diabetes +$13.0M (+7%); Other −$9.7M (-17%).
Accendra Health, Q2 2026: revenue $613M (-10% year over year), operating margin -5.7%, net loss $89.1M, operating cash flow −$26.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Diabetes | $199M | $186M | $13.0M | +7% |
| Sleep therapy | $149M | $167M | −$18.3M | -11% |
| Home respiratory therapy | $91.0M | $97.2M | −$6.2M | -6% |
| Ostomy | $55.7M | $51.3M | $4.3M | +8% |
| Other | $47.7M | $57.4M | −$9.7M | -17% |
| Wound care | $40.2M | $39.4M | $791K | +2% |
| Urology | $31.3M | $29.8M | $1.5M | +5% |
| Revenue | $613M | $628M | −$14.5M | -2% |
| Net loss | $89.1M | $6.5M | $82.6M | 14× |
| Costs & expenses | $702M | $644M | $58.3M | +9% |
| Operating costs | $648M | $611M | $37.7M | +6% |
| Interest & other, net | $52.5M | $33.4M | $19.1M | +57% |
| Income tax | $1.4M | −$9.8M | $11.2M | — |
| Cost of revenue | $350M | $350M | $75K | 0% |
| SG&A | $244M | $255M | −$11.7M | -5% |
| Other operating costs | $55.0M | $5.7M | $49.3M | +869% |
| Operating cash sources | $95.7M | $115M | −$19.2M | -17% |
| Depreciation & amortization | $65.7M | $61.7M | $4.0M | +6% |
| Share-based compensation | $4.0M | $3.1M | $914K | +30% |
| Cash used in operations | $26.0M | $50.1M | −$24.1M | -48% |
| Net loss absorbed | $89.1M | $6.5M | $82.6M | 14× |
| Working capital & other | $6.6M | $108M | −$102M | -94% |
Questions
How much did Accendra Health's revenue grow quarter over quarter in Q2 2026?
Accendra Health's revenue fell $14.5M (-2%) from $628M in Q1 2026 to $613M in Q2 2026.
What drove Accendra Health's revenue change in Q2 2026?
Sleep therapy −$18.3M (-11%); Diabetes +$13.0M (+7%); Other −$9.7M (-17%).